Naive-Like T Cells Linked to CAR T Durability

Higher proportions of less-differentiated T cells were associated with longer progression-free survival in a 783-patient lymphoma analysis

1

In 580 patients with non-Hodgkin lymphoma treated with axi-cel, a higher proportion of CCR7- and CD45RA-positive naive-like T cells was associated with longer progression-free survival.
2

Patients in the highest naive-like T-cell group had a 54% lower relative hazard of progression or death and a higher ongoing response rate than those in the lowest group (59.3% vs 29.2%).
3

The association persisted after adjustment for prognostic factors and was validated in an independent cohort of 203 patients treated with axi-cel-based therapies or brexucabtagene autoleucel.
4

More prior lines of therapy were associated with fewer naive-like T cells in both starting material and final CAR T-cell products, but final-product proportions were more strongly associated with outc
5

The findings are associative, not causal, and may not generalize beyond the CD28-based CAR T products studied in patients with lymphoma.

1